Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Neuroimmunomodulation 2002–03;10:247–260

Glucocorticoids and Inflammation Revisited: The State of the Art

NIH Clinical Staff Conference

Franchimont D.a,b · Kino T.a · Galon J.c · Meduri G.U.d · Chrousos G.P.a

Author affiliations

aPediatric and Reproductive Endocrinology Branch, NICHD, NIH, Bethesda, Md., USA; bGastroenterology-Internal Medicine Department, Erasme University Hospital, Brussels, Belgium; cINSERM 255, Clinical and Cellular Immunology, Curie Institute, Paris, France; dMemphis Lung Research Program, Department of Medicine, Divisions of Pulmonary and Critical Care Medicine, University of Tennessee Health Science Center, Memphis, Tenn., USA

Corresponding Author

Denis P. Franchimont, MD, and George P. Chrousos, MD

Pediatric and Reproductive Endocrinology Branch

National Institute of Child Health and Human Development

National Institutes of Health, Bethesda, MD 20892-1583 (USA)

Tel. +1 301 496 5800, Fax +1 301 402 0884, E-Mail chrousog@mail.nih.gov

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Glucocorticoids have been used in the treatment of inflammatory and autoimmune diseases and to prevent graft rejection for over 50 years. These hormones exert their effects through cytoplasmic, heat shock protein-bound glucocorticoid receptors that translocate into the nucleus, where they regulate the transcriptional activity of responsive genes by binding to specific promoter DNA sequences (transactivation) or by interacting with transcription factors (transrepression). By interacting with different signaling pathways, newly characterized nuclear receptor coregulators enhance or diminish the actions of glucocorticoids, thus explaining the gene-, cell-, tissue- and context-dependent actions of glucocorticoids. Glucocorticoids modulate genes involved in the priming of the innate immune response, while their actions on the adaptive immune response are to suppress cellular [T helper (Th)1-directed] immunity and promote humoral (Th2-directed) immunity and tolerance. The past decade has produced new insights into the mechanisms of glucocorticoid sensitivity and resistance of inflammatory, autoimmune and allergic diseases. Both the quality and severity of the inflammatory stimulus, as well as the genetics and constitution of the patient, play key roles in the glucocorticoid sensitivity, dependency and resistance of these diseases. Although glucocorticoids increase susceptibility to opportunistic infections, they are also highly beneficial in the presence of serious systemic inflammation, such as that observed in septic shock and acute respiratory distress syndrome, when administered in a sustained fashion throughout the course of the disease. Glucocorticoids produce their cardiovascular, metabolic and antigrowth side effects through molecular mechanisms distinct from those involved in immunomodulation. Fortunately, the first generation of tissue- and immune- versus cardiovascular/metabolic effect-selective glucocorticoids is available for study and further improvement. ‘Designer’ glucocorticoids promise to be a great new advance in the therapy of inflammatory diseases.

© 2003 S. Karger AG, Basel


  1. Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996;17:245–261.
  2. Bamberger CM, Bamberger AM, de Castro M, Chrousos GP: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995;95:2435–2441.
  3. McKenna NJ, Lanz RB, O’Malley BW: Nuclear receptor coregulators: Cellular and molecular biology. Endocr Rev 1999;20:321–344.
  4. Glass CK, Rosenfeld MG: The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121–141.
  5. McKay LI, Cidlowski JA: Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435–459.
  6. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286–290.
  7. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr: Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995;270:283–286.
  8. Wissink S, van Heerde EC, van der Burg B, van der Saag PT: A dual mechanism mediates repression of NF-kappa B activity by glucocorticoids. Mol Endocrinol 1998;12:355–363.
  9. Meagher LC, Cousin JM, Seckl JR, Haslett C: Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996;156:4422–4428.
  10. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G: A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA 1992;89:9991–9995.
  11. Perretti M, Croxtall JD, Wheller SK, Goulding NJ, Hannon R, Flower RJ: Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration. Nat Med 1996;2:1259–1262.
  12. Nakagawa M, Bondy GP, Waisman D, Minshall D, Hogg JC, van Eeden SF: The effect of glucocorticoids on the expression of L-selectin on polymorphonuclear leukocyte. Blood 1999;93:2730–2737.
  13. Juan M, Mullol J, Roca-Ferrer J, Fuentes M, Perez M, Vilardell C, Yague J, Picado C: Regulation of ICAM-3 and other adhesion molecule expressions on eosinophils in vitro. Effects of dexamethasone. Allergy 1999;54:1293–1298.
  14. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE: Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol 1999;163:1545–1551.
  15. Liu Y, Cousin JM, Hughes J, Van Damme J, Seckl JR, Haslett C, Dransfield I, Savill J, Rossi AG: Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 1999;162:3639–3646.
  16. Pan LY, Mendel DB, Zurlo J, Guyre PM: Regulation of the steady state level of Fc gamma RI mRNA by IFN-gamma and dexamethasone in human monocytes, neutrophils, and U-937 cells. J Immunol 1990;145:267–275.
  17. Hogger P, Dreier J, Droste A, Buck F, Sorg C: Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol 1998;161:1883–1890.
  18. Yoss EB, Spannhake EW, Flynn JT, Fish JE, Peters SP: Arachidonic acid metabolism in normal human alveolar macrophages: Stimulus specificity for mediator release and phospholipid metabolism, and pharmacologic modulation in vitro and in vivo. Am J Respir Cell Mol Biol 1990;2:69–80.
  19. Sebaldt RJ, Sheller JR, Oates JA, Roberts LJ 2nd, FitzGerald GA: Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci USA 1990;87:6974–6978.
  20. Riddick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD: Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem 1997;246:112–118.
  21. Amezaga MA, Bazzoni F, Sorio C, Rossi F, Cassatella MA: Evidence for the involvement of distinct signal transduction pathways in the regulation of constitutive and interferon gamma-dependent gene expression of NADPH oxidase components (gp91-phox, p47-phox, and p22-phox) and high-affinity receptor for IgG (Fc gamma R-I) in human polymorphonuclear leukocytes. Blood 1992;79:735–744.
  22. Salvemini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P, Masferrer JL: Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest 1995;96:301–308.
  23. Piemonti L, Monti P, Allavena P, Sironi M, Soldini L, Leone BE, Socci C, Di Carlo V: Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162:6473–6481.
  24. Ramierz F, Fowell DJ, Puklavec M, Simmonds S, Mason D: Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406–2412.
  25. Blotta MH, DeKruyff RH, Umetsu DT: Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997;158:5589–5595.
  26. Wu CY, Wang K, McDyer JF, Seder RA: Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998;161:2723–2730.
  27. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, Frucht DM, Chrousos GP, O’Shea JJ: Inhibition of Th1 immune response by glucocorticoids: Dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. J Immunol 2000;164:1768–1774.
  28. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A: In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002;195:603–616.
  29. Wu CY, Sarfati M, Heusser C, Fournier S, Rubio-Trujillo M, Peleman R, Delespesse G: Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes. J Clin Invest 1991;87:870–877.
  30. Kimata H, Lindley I, Furusho K: Effect of hydrocortisone on spontaneous IgE and IgG4 production in atopic patients. J Immunol 1995;154:3557–3566.
  31. Barnes PJ: Corticosteroids, IgE, and atopy. J Clin Invest 2001;107:265–266.
  32. Wilckens T, De Rijk R: Glucocorticoids and immune function: Unknown dimensions and new frontiers. Immunol Today 1997;18:418–424.
  33. Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359–368.
    External Resources
  34. Zacharchuk CM, Mercep M, Chakraborti PK, Simons SS Jr, Ashwell JD: Programmed T lymphocyte death. Cell activation- and steroid-induced pathways are mutually antagonistic. J Immunol 1990;145:4037–4045.
  35. Ashwell JD, Lu FW, Vacchio MS: Glucocorticoids in T cell development and function. Annu Rev Immunol 2000;18:309–345.
  36. Purton JF, Boyd RL, Cole TJ, Godfrey DI: Intrathymic T cell development and selection proceeds normally in the absence of glucocorticoid receptor signaling. Immunity 2000;13:179–186.
  37. Van Laethem F, Baus E, Smyth LA, Andris F, Bex F, Urbain U, Kioussis D, Leo O: Glucocorticoids attenuate T cell receptor signaling. J Exp Med 2001;193:803–814.
  38. Gonzalo JA, Gonzalez-Garcia A, Martinez C, Kroemer G: Glucocorticoid-mediated control of the activation and clonal deletion of peripheral T cells in vivo. J Exp Med 1993;177:1239–1246.
  39. Galon J, Franchimont D, Hiroi N, Frey G, Boettner A, Ehrhart-Bornstein M, O’Shea JJ, Chrousos GP, Bornstein SR: Gene profiling reveals previously unknown permissive and suppressive actions of glucocorticoids on immune cells. FASEB J 2002;16:61–71.
  40. Franchimont D, Galon J, Vacchio M, Fan S, Visconti R, Frucht D, Geenen V, Chrousos G, Ashwell J, O’Shea J: Positive effects of glucocorticoids on T cell function by up-regulation of IL-7 receptor α. J Immunol 2002;168:2212–2217.
  41. Barnes PJ, Greening AP, Crompton GK: Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125–S140.
  42. Chrousos GP, Castro M, Leung DY, Webster E, Kino T, Bamberger C, Elliot S, Stratakis C, Karl M: Molecular mechanisms of glucocorticoid resistance/hypersensitivity. Potential clinical implications. Am J Respir Crit Care Med 1996;154:S39–S44.
  43. Franchimont DP, Louis E, Croes F, Belaiche J: Clinical pattern of corticosteroid dependent Crohn’s disease. Eur J Gastroenterol Hepatol 1998;10:821–825.
  44. Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT: Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999;117:645–652.
  45. Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, Croes F, Dupont P, Davin L, Omri S, Rutgeerts P, Belaiche J: Tumour necrosis factor (TNF) gene polymorphism in Crohn’s disease (CD): Influence on disease behaviour? Clin Exp Immunol 2000;119:64–68.
  46. Franchimont D, Martens H, Hagelstein MT, Louis E, Dewe W, Chrousos GP, Belaiche J, Geenen V: Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: Potential regulation of the glucocorticoid receptor. J Clin Endocrinol Metab 1999;84:2834–2839.
  47. Leung DY, Hamid Q, Vottero A, Szefler SJ, Surs W, Minshall E, Chrousos GP, Klemm DJ: Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567–1574.
  48. Honda M, Orii F, Ayabe T, Imai S, Ashida T, Obara T, Kohgo Y: Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859–866.
  49. Barnes PJ, Karin M: Nuclear factor-kappa B: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066–1071.
  50. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH: Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest 1998;102:2156–2164.
  51. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ: Tumor necrosis factor alpha and interleukin 1 beta enhance the cortisone/cortisol shuttle. J Exp Med 1997;186:189–198.
  52. Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O’Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D: High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000;118:279–288.
  53. Diaz-Borjon A, Richaud-Patin Y, Alvarado de la Barrera C, Jakez-Ocampo J, Ruiz-Arguelles A, Llorente L: Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. 2. Increased P-glycoprotein activity in lymphocytes from systemic lupus erythematosus patients might affect steroid requirements for disease control. Joint Bone Spine 2000;67:40–48.
  54. Krafft P, Fridrich P, Pernerstorfer T, Fitzgerald RD, Koc D, Schneider B, Hammerle AF, Steltzer H: The acute respiratory distress syndrome: Definitions, severity and clinical outcome. An analysis of 101 clinical investigations. Intensive Care Med 1996;22:519–529.
  55. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A: Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome. Chest 1995;108:1303–1314.
  56. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, Leeper K: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062–1073.
  57. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351–1362.
  58. Briegel J, Forst H, Hellinger H, Haller M: Contribution of cortisol deficiency to septic shock. Lancet 1991;338:507–508.
  59. Reincke M, Allolio B, Wurth G, Winkelmann W: The hypothalamic-pituitary-adrenal axis in critical illness: Response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151–156.
  60. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E: A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000;283:1038–1045.
  61. Meduri GU, Chrousos GP: Duration of glucocorticoid treatment and outcome in sepsis: Is the right drug used the wrong way? Chest 1998;114:355–360.
  62. Chrousos GP, Detera-Wadleigh SD, Karl M: Syndromes of glucocorticoid resistance. Ann Intern Med 1993;119:1113–1124.
  63. Molijn GJ, Spek JJ, van Uffelen JC, de Jong FH, Brinkmann AO, Bruining HA, Lamberts SW, Koper JW: Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995;80:1799–1803.
  64. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645–650.
  65. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998;280:159–165.
  66. Meduri GU, Tolley EA, Chrousos GP, Stentz F: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: Evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983–991.
  67. Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998;851:311–335.
  68. Chrousos GP: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: Neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000;24(suppl 2): S50–S55.
  69. Chrousos GP, Harris AG: Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 2. Review of the literature. Neuroimmunomodulation 1998;5:288–308.
  70. Chrousos GP, Harris AG: Hypothalamic-pituitary-adrenal axis suppression and inhaled corticosteroid therapy. 1. General principles. Neuroimmunomodulation 1998;5:277–287.
  71. Bourguet W, Germain P, Gronemeyer H: Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends Pharmacol Sci 2000;21:381–388.
    External Resources
  72. Bamberger CM, Else T, Bamberger AM, Beil FU, Schulte HM: Dissociative glucocorticoid activity of medroxyprogesterone acetate in normal human lymphocytes. J Clin Endocrinol Metab 1999;84:4055–4061.
  73. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, Gronemeyer H, Resche-Rigon M: Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245–1255.
  74. Szapary D, Huang Y, Simons SS Jr: Opposing effects of corepressor and coactivators in determining the dose-response curve of agonists, and residual agonist activity of antagonists, for glucocorticoid receptor-regulated gene expression. Mol Endocrinol 1999;13:2108–2121.

Article / Publication Details

First-Page Preview
Abstract of Review

Published online: May 16, 2003

Number of Print Pages: 14
Number of Figures: 5
Number of Tables: 3

ISSN: 1021-7401 (Print)
eISSN: 1423-0216 (Online)

For additional information: https://www.karger.com/NIM